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BACKGROUND: The role of drug- coated balloons (DCBs) in the treatment of de novo coronary lesions is not well established.
METHODS AND RESULTS: Electronic databases and major conference proceedings were searched for randomized controlled 
trials that compared DCBs with stents or angioplasty for de novo coronary lesions. The primary outcome was target lesion 
revascularization. Summary estimates were conducted using random- effects analysis complemented by several subgroup 
and sensitivity analyses. A total of 14 randomized controlled trials with 2483 patients were included. At a mean follow up of 
12 months, DCBs were associated with no difference in the incidence of target lesion revascularization as compared with 
alternative strategies (risk ratio [RR], 0.79; 95% CI, 0.35–1.76). There was no difference in treatment effect based on the indica-
tion (ie, small- vessel disease, myocardial infarction, bifurcation, or high bleeding risk) (Pinteraction=0.22). DCBs were associated 
with lower target lesion revascularization compared with bare metal stents and similar target lesion revascularization com-
pared with drug- eluting stents (Pinteraction=0.03). There was no difference between DCBs and control in terms of major adverse 
cardiac events, vessel thrombosis, or cardiovascular mortality. However, DCBs were associated with a lower incidence of 
myocardial infarction (RR, 0.48; 95% CI, 0.25–0.90) and all-cause mortality (RR, 0.45; 95% CI, 0.22–0.94).
CONCLUSIONS: In patients with de novo coronary lesions, use of DCBs was associated with comparable clinical outcomes irre-
spective of the indication or comparator device. DCBs had a similar rate of target lesion revascularization compared with drug- 
eluting stents. A randomized trial powered for clinical outcomes and evaluating the role of DCBs for all- comers is warranted.
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Drug- eluting stents (DESs), particularly second- generation, remain the cornerstone manage-ment during percutaneous coronary intervention.1 
Coronary restenosis as a result of the persistence of 
the metallic struts within the vessel as well as the need 
for dual antiplatelet therapy remain major limitations 
even with the current generation of DESs.2,3 In this 
context, drug- coated balloons (DCBs) offer an attrac-
tive therapeutic modality because these devices allow 
for local delivery of the antiproliferative agent directly 
into the artery wall with a single balloon inflation without 
the need for the metallic implant.4 Several randomized 
trials have established the role of DCBs in treatment of 
in- stent restenosis of both DESs and bare metal stents 
(BMSs),5–8 and the use of DCBs is currently endorsed 
by the 2018 European Society of Cardiology guidelines 
for myocardial revascularization as a class I recom-
mendation for this indication.9
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However, the role of DCBs is not as established for 
de novo coronary lesions.4 Recently, several small- 
to- moderate–sized, randomized trials have evaluated 
the merits of DCBs for patients with small- vessel dis-
ease,10,11 high risk of bleeding,12 and myocardial infarc-
tion (MI).13,14 However, most of these individual trials 
were not powered to assess the differences in clinical 
outcomes.10,13,14 Moreover, the trials that were powered 
for clinical outcomes were noninferiority trials and did 
not routinely evaluate angiographic outcomes.11–13 To 
address this knowledge gap, we performed a com-
prehensive systematic review and meta- analysis of 
randomized trials to evaluate the impact of DCBs for 
de novo coronary lesions on angiographic and clinical 
outcomes.
METHODS
The authors declare that all supporting data are avail-
able within the article (and in the accompanying sup-
plementary material online).
Data Sources and Search Strategy
Electronic databases, including MEDLINE, Embase, 
and the Cochrane Register of Controlled Trials, as well 
as major scientific sessions, were searched without 
language restriction from inception through November 
2019 using the search algorithm in Table S1. The bib-
liography of the retrieved articles was reviewed. The 
search was independently performed by 2 authors 
(I.Y.E., F.A.). The protocol for this meta- analysis was 
prospectively registered at the PROSPERO inter-
national prospective register of systematic reviews 
(CRD42019143329),15 and was conducted accord-
ing to the Preferred Reporting Items for Systematic 
Reviews and Meta- Analyses guidelines.16
Selection Criteria and Data Extraction
Trials that randomized patients with obstructive de 
novo coronary lesions to DCBs versus any compara-
tor were included (ie, DES, BMS, angioplasty only). We 
excluded trials that electively performed routine BMS 
placement after DCBs, but included trials that permit-
ted bailout stent placement after DCBs. Clinical and 
angiographic data from the longest available reported 
follow- up time were preferentially used. Observational 
studies were excluded for inherent risk of bias. Two 
independent authors (I.Y.E., A.Y.E.) extracted data on 
study design, sample size, intervention strategies, 
outcomes, and other study characteristics from the 
included studies. Discrepancies were resolved by 
consensus.
Assessment of Quality of Included 
Studies
The Cochrane Collaboration’s tool was used for the 
assessment of the risk of bias. This consists of 7 points 
that test for selection, performance, detection, attri-
tion, reporting, and other biases.17 Performance bias 
(ie, blinding of participants and physicians) was found 
to be irrelevant due to the interventional nature in both 
arms. The overall risk of bias for each trial was clas-
sified as low, unclear, or high risk, based on whether 
level of bias in each domain could have resulted in bi-
ases in risk estimation.
Outcomes
The primary clinical outcome was target lesion revas-
cularization (TLR). The secondary clinical outcomes 
included: major adverse cardiac events, as defined by 
the individual trials (Table S2); target vessel revasculari-
zation; MI; vessel thrombosis; cardiovascular mortal-
ity; and all- cause mortality. The following angiographic 
outcomes were assessed: minimum lumen diameter 




• In patients with de novo coronary lesions, drug-
coated balloons were associated with com-
parable clinical outcomes irrespective of the 
indication or comparator device.
• Drug-coated balloons had a similar rate of tar-
get lesion revascularization compared with 
drug-eluting stents.
What Are the Clinical Implications?
• These findings suggest the value of drug-
coated balloons as an attractive “leave-nothing-
behind strategy” for selected patients with de 
novo coronary lesions provided a satisfactory 
result is obtained after lesion predilation.
• A randomized trial powered for clinical out-
comes and evaluating the role of drug-coated 
balloons for all-comers is warranted.
Nonstandard Abbreviations and Acronyms
BMS bare metal stent
DCB drug-coated balloon
DES drug-eluting stents
MLD minimum lumen diameter
MI myocardial infarction
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Statistical Analysis
Outcomes were evaluated by an intention- to- treat 
analysis. Random- effects summary risk ratios were 
primarily estimated with the DerSimonian and Laird 
model, because we anticipated a high degree of 
statistical heterogeneity.18 Summary odds ratios 
were also estimated with a Peto model as a second-
ary analysis due to the low incidence of events.19 
Statistical heterogeneity was assessed using the 
Cochrane Q and I2 statistics.20 Egger’s method was 
used to calculate publication bias.21 Standardized 
mean differences were used for continuous vari-
ables. All P- values were 2- tailed, with statistical sig-
nificance set at 0.05, and CIs were calculated at the 
95% level for the overall estimates effect. All analyses 
were performed using the RStudio software meta 
package (RStudio, Inc, Boston, MA).
The following prespecified subgroup analyses were 
performed for the primary outcome (TLR): (1) accord-
ing to indication; and (2) by comparing DESs versus 
BMSs. In addition, the following prespecified sensitivity 
analyses for TLR were also conducted by: (1) excluding 
trials using the first- generation DCB, which is no longer 
available22; (2) excluding trials using angioplasty alone 
in the control arm; (3) limiting to trials utilizing second- 
generation DESs as the control; and (4) excluding trials 
with high risk of bias. Random- effects meta- regression 
analyses for the primary outcome were prespecified in 
relation to baseline reference vessel diameter, diabetes 
mellitus, and proportion of bailout stent placement in 
the DCBs arm.23 Finally, a sensitivity analysis limited 
to trials using second- generation DESs as the control 
was performed for the angiographic outcomes, and 
a sensitivity analysis limited to trials that defined MI 




The systematic search identified 502 studies after 
removal of the duplicates, among which 37 were re-
viewed for eligibility. The final number of records in-
cluded in this meta- analysis was 14 trials from 15 
Figure 1. Study search diagram.
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reports (Figure 1).10–14,22,24–32 One trial reported angio-
graphic and clinical outcomes at 6 months26 and re-
ported an extended follow- up for the clinical outcomes 
at 36 months.27 A total of 2483 patients were included: 
1268 in the DCBs group and 1215 in the control group. 
The indication for DCBs was small- vessel disease in 
5 trials,10,11,22,24–27 MI in 3 studies,13,14,28 high bleeding 
risk in 2 trials,12,29 bifurcational lesions in 2 studies,30,31 
and unspecified de novo lesions in 1 study.32 In the 
bifurcational lesion trials, 1 trial compared “plain old” 
balloon angioplasty followed by DCB versus plain old 
balloon angioplasty alone to the main or side branch,30 
whereas the other trial randomized patients with bifur-
cational lesions to a strategy of side- branch dilation 
with DCB versus plain old balloon angioplasty.31 The 
SeQuent Please paclitaxel- coated balloon was used by 
most of the included studies (9 of 14). Only 1 trial tested 
the Dior paclitaxel- coated balloon, which is no longer 
available.22 The control group was exclusively second- 
generation DES in 6 trials,10,11,14,24,28,32 first- generation 
DESs in 2 trials,22,26 BMSs in 2 trials,12,29 and plain old 
balloon angioplasty alone in 3 trials.25,30,31 In 1 trial, the 
control was second- generation DESs or BMSs, and 
a subgroup analysis was reported for the outcomes 
based on the stent type.13 The weighted mean refer-
ence vessel diameter was 2.5 mm. Table shows the 
baseline trial characteristics, follow- up duration, and 
interventional strategies. Table S3 summarizes the 
pertinent patient demographics and trial information. 
Performance bias was unclear in all the trials. One trial 
was at high risk for detection bias and unclear for allo-
cation bias,32 otherwise the remainder of the trials were 
considered to be of high quality (Table S4).
Angiographic Outcomes
Routine angiographic follow- up was performed at a 
weighted mean of 7 (range, 6–9)  months. There was 
no difference between DCBs and control in terms of 
MLD (1.9 mm versus 2.0 mm; standardized mean dif-
ference, −0.13; 95% CI, −0.32 to 0.06; P=0.17), diam-
eter stenosis (28.0% versus 28.1%; standardized mean 
difference, 0.22, 95% CI, −6.92 to 7.36; P=0.95), and 
binary restenosis (13.9% versus 16.3%; RR, 0.83; 95% 
CI, 0.40–1.71; P=0.61). However, DCBs were associated 
with lower late lumen loss (0.08 mm versus 0.24 mm; 
standardized mean difference, −0.17; 95% CI, −0.24 to 
−0.10; P<0.0001) (Figure 2). There was a significant de-
gree of statistical heterogeneity observed for the angio-
graphic outcomes (I2 ranged from 60% to 94%), which 
was explained on the sensitivity analysis limited to trials 
comparing DCBs with second- generation DESs (I2=0% 
for all the outcomes, except for diameter stenosis where 
I2=56%). The findings of the sensitivity analysis were con-
sistent with the main analysis for all angiographic out-
comes except for a lower MLD with DCBs (Figure S1).
Target Lesion Revascularization
The weighted mean follow up for the clinical out-
comes was 12 (range, 6–36)  months. There was 
Figure 2. Summary plots for the angiographic outcomes.
The relative size of the data markers indicates weight of sample size from each study. DCB indicates drug- coated balloon; MD, mean 
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no difference in the incidence of TLR with DCBs 
compared with control (random effects: 4.6% ver-
sus 5.1%; RR, 0.79; 95% CI, 0.35–1.76; P=0.56; 
fixed effects: OR, 0.91; 95% CI, 0.58–1.44; P=0.69) 
(Figure  3). There was no evidence of publication 
bias using Egger’s test (P=0.45). The outcome was 
characterized by moderate heterogeneity (I2=50%; 
χ2=22.1; Pheterogeneity=0.02). DCBs showed similar TLR 
compared with control, irrespective of the indica-
tion (Pinteraction=0.22) (Figure 4). The incidence of TLR 
was similar when DCBs compared with DESs (RR, 
1.37; 95% CI, 0.62–3.05; I2=34%), but DCBs were 
associated with a lower incidence of TLR compared 
with BMSs (RR, 0.19; 95% CI, 0.04–1.00; I2=0%) 
(Pinteraction=0.03) (Figure  5). The findings of the pre-
specified sensitivity analyses for TLR were consist-
ent with the overall analysis: (1) excluding trials that 
utilized the older generation DCBs (RR, 0.76; 95% CI, 
0.35–1.65; I2=43%; χ2=17.6; Pheterogeneity=0.06) (Figure 
S2); (2) excluding trials using angioplasty alone in the 
control arm (RR, 0.97; 95% CI, 0.42–2.27; I2=45%; 
χ2=14.5; Pheterogeneity=0.07) (Figure S3); (3) limited 
to trials utilizing second- generation DESs as con-
trol (RR, 1.65; 95% CI, 0.65–4.34; I2=0%; χ2=2.9; 
Pheterogeneity=0.57) (Figure S4); and (4) excluding the 
trial with high risk of bias (RR, 0.97; 95% CI, 0.45–
2.12; I2=52%; χ2=21.0; Pheterogeneity=0.02) (Figure S5). 
Meta- regression analysis did not identify a difference 
in the treatment effect based on baseline reference 
vessel diameter (P=0.81), diabetes mellitus (P=0.37), 
and proportion of bailout stent placement (P=0.63).
Secondary Clinical Outcomes
Compared with control, DCBs were associated with 
no difference in the incidence of target vessel revas-
cularization (6.0% versus 5.3%; RR, 1.21; 95% CI, 
0.60–2.44; P=0.59; I2=52%; χ2=8.3; Pheterogeneity=0.08), 
major adverse cardiac events (6.9% versus 9.1%; RR, 
0.83; 95% CI, 0.50–1.36; P=0.46; I2=53%; χ2=23.3; 
Pheterogeneity=0.02), vessel thrombosis (0.3% versus 
1.1%; RR, 0.38; 95% CI, 0.13–1.13; P=0.08; I2=0%; 
χ2=0.5; Pheterogeneity=0.91), and cardiovascular mor-
tality (1.5% versus 1.5%; RR, 0.90; 95% CI, 0.27–
3.00; P=0.86; I2=56%; χ2=6.8; Pheterogeneity=0.08). 
Importantly, DCBs were associated with a lower inci-
dence of all- cause mortality (1.2% versus 2.9%; RR, 
0.45; 95% CI, 0.22–0.94; P=0.03; I2=0%; χ2=0.78; 
Pheterogeneity=0.85), and MI (1.1% versus 2.9%; RR, 
0.48; 95% CI, 0.25–0.90; P=0.02; I2=0%; χ2=6.2; 
Pheterogeneity=0.62) (Figures 6 and S6 through S11). In 
the sensitivity analysis limited to trials that defined 
MI as spontaneous MI, DCBs were associated with 
lower incidence of spontaneous MI (RR, 0.49; 95% 
CI, 0.25–0.96; P=0.04; I2=0%) (Figure S12). There was 
no evidence of publication bias for any of the second-
ary clinical outcomes using Egger’s test (all P>0.05).
DISCUSSION
In this meta- analysis of 14 randomized trials including 
2483 patients with de novo coronary lesions undergo-
ing percutaneous coronary intervention irrespective of 
Figure 3. Summary plot for target lesion revascularization.
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indication, we documented that DCBs were associated 
with similar MLD, diameter stenosis, binary restenosis, 
and lower late lumen loss compared with control on 
routine angiographic follow up at a mean of 7 months. 
These findings were similar when DCBs were only 
compared with second- generation DESs (except that 
DCBs were associated with lower MLD). At a mean 
of 12  months, DCBs were associated with no differ-
ence in the incidence of TLR compared with control. 
This effect was consistent, regardless of indication (ie, 
small- vessel disease, high bleeding risk, MI, or bifur-
cational lesions), and on multiple sensitivity analyses, 
including comparing DCBs with second- generation 
DESs. DCBs were associated with lower risk of TLR 
compared with BMS. There was a moderate degree 
of statistical heterogeneity for TLR, which was partly 
explained by our subgroup analysis comparing DCBs 
with DESs versus BMSs, and on the sensitivity analysis 
limited to second- generation DESs. DCBs were also 
associated with no difference in the incidence of target 
vessel revascularization, major adverse cardiac events, 
vessel thrombosis, and cardiovascular mortality. 
Importantly, the incidence of all- cause mortality and MI 
(even when spontaneous MI was analyzed separately) 
Figure 4. Subgroup analysis for target lesion revascularization according to indication.
The relative size of the data markers indicates weight of sample size from each study. There was no difference in treatment effect 
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was lower with DCBs. However, these findings were 
based on a small number of trials and the number of 
events was low, and therefore should be only consid-
ered as hypothesis- generating. Altogether, our findings 
strongly suggest the value of DCBs as an attractive 
“leave–nothing- behind strategy” for selected patients 
with de novo coronary lesions provided a satisfactory 
result is obtained after lesion predilation.
DCBs offer the advantage of locally deliver-
ing the antiproliferative drug without the need for 
Figure 5. Subgroup analysis for target lesion revascularization comparing bare metal and drug- eluting stents.
The relative size of the data markers indicates the weight of the sample size from each study. Drug- coated balloon use was associated 
with lower target lesion revascularization compared with bare metal stents and similar target lesion revascularization compared with 
drug- eluting stents (Pinteraction=0.03). DCB indicates drug- coated balloon; and TLR, target lesion revascularization.
Figure 6. Forest plots for the clinical outcomes evaluated in this meta- analysis.
For each comparison, boxes and horizontal lines correspond to the respective point estimate and accompanying 95% CI. DCB 
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metal struts, thus directly inhibiting the process 
of  neointimal hyperplasia and negative remod-
eling.4 Although use of DCBs in patients with in- 
stent  restenosis has been extensively investigated,9 
trials evaluating DCBs for de novo lesions have 
been small and evaluated specific indications. Our 
meta- analysis, including the most recent trials, has 
demonstrated that DCBs were associated with fa-
vorable clinical outcomes irrespective of the indica-
tion, even when compared with second- generation 
DESs. Although most  patients undergoing percu-
taneous coronary intervention are treated with a 
second- generation DES,1 BMSs are still used in a 
minority of patients, such as those with a high risk of 
bleeding to minimize the duration of antiplatelet ther-
apy. Our meta- analysis showed that DCBs represent 
a reasonable therapeutic strategy for this subset of 
patients.
Second- generation DESs may not offer an effec-
tive therapeutic strategy in small vessels due to the 
late lumen loss resulting in late in- stent restenosis.34 In 
this challenging setting, several randomized trials have 
shown that DCBs are noninferior to DESs for major 
adverse cardiac events.10,11 By significantly increas-
ing the sample size, the current meta- analysis has 
extended our knowledge by showing that DCBs are 
associated with similar TLR compared with any con-
trol, including second- generation DESs. Moreover, our 
meta- regression analysis has shown that there was no 
difference in treatment effect based on the reference 
vessel diameter.
One meta- analysis of randomized trials has raised 
some concerns about late mortality with DCBs for 
patients with peripheral artery disease.35 That meta- 
analysis was subject to several limitations,36 and the late 
mortality finding was not replicated in several large ob-
servational studies and patient- level meta- analysis.37,38 
Our meta- analysis provides some support for the use 
of DCBs for coronary lesions. However, the lower mor-
tality seen with DCBs in our meta- analysis should be 
interpreted with caution given the limited number of 
studies that evaluated all- cause mortality and the low 
number of events.
Previous meta- analyses addressed use of DCBs 
for a specific indication, such as small- vessel dis-
ease or bifurcational lesions.39–41 In addition, those 
meta- analyses included observational studies, 
which are prone to ascertainment and selection 
biases.39–41 Furthermore, those works did not include 
the results of several recently published and presented 
trials.10,13,14,24 The present meta- analysis only included 
randomized trials and has provided a comprehensive 
overview of the angiographic and clinical outcomes of 
DCBs irrespective of indication. In addition, we per-
formed several subgroup and sensitivity analyses  to 
explore the statistical heterogeneity.
Our meta- analysis has several limitations. First, 
although all the included studies used a paclitaxel- 
coated balloon, there are several pharmacokinetic 
differences between the devices. For example, one 
trial used the first- generation Drior paclitaxel- coated 
balloon, which was shown to be inferior in terms of 
deliverability and is no longer available. Thus, we 
performed a sensitivity analysis excluding this trial 
for the primary clinical outcome. Second, there were 
differences in the core laboratory assessment of 
the angiographic outcomes across the trials, which 
could be a source of the significant heterogeneity 
noted with these outcomes. However, we observed 
no heterogeneity for most of the angiographic out-
comes on the sensitivity analysis comparing DCBs 
with second- generation DESs. Third, we noted a 
moderate degree of statistical heterogeneity for the 
primary clinical outcome (ie, TLR). We attempted to 
mitigate this by using a random- effects model. In ad-
dition, we performed multiple subgroup, sensitivity, 
and meta- regression analyses to explore the hetero-
geneity; however, the number of studies included 
in some of these subgroup and sensitivity analyses 
was small, so the findings can only be considered as 
hypothesis- generating. Fourth, one of the included 
trials was at high risk for bias,32 so we performed 
a sensitivity analysis excluding that trial for TLR. 
Fifth, despite the extensive subgroup, sensitivity, 
and meta- regression analyses conducted, there may 
be some considerations about clinical and method-
ologic heterogeneity, because the meta- analysis in-
cluded different comparators and the indication for 
DCBs were variable. Finally, the lack of patient- level 
data precluded a careful evaluation for the patient 
and lesion characteristics that would benefit most 
from DCBs.
CONCLUSIONS
In this meta- analysis of 14 randomized trials compris-
ing 2483 patients with de novo coronary lesions, DCBs 
were associated with similar MLD, diameter stenosis, 
acute lumen gain, binary restenosis, and lower late 
lumen loss compared with control on routine angio-
graphic follow up. There was no difference in the inci-
dence of TLR between DCBs compared with control. 
This effect was observed regardless of indication (ie, 
small- vessel disease, high bleeding risk, MI, or bifur-
cational lesions), and was maintained when compared 
with second- generation DES alone. Finally, DCBs were 
associated with lower risk of MI and all- cause mortal-
ity, albeit with a low number of events, so our work 
should be only considered hypothesis- generating. Our 
findings support the need for a randomized trial pow-
ered for clinical outcomes evaluating the role of the 




 http://ahajournals.org by on M
arch 2, 2021
J Am Heart Assoc. 2020;9:e016224. DOI: 10.1161/JAHA.120.016224 10
Elgendy et al DCBs for De Novo Coronary Lesions
ARTICLE INFORMATION
Received February 12, 2020; accepted April 8, 2020.
Affiliations
From the Division of Cardiology, Massachusetts General Hospital and 
Harvard Medical School, Boston, MA (I.Y.E.); Department of Medicine, 
Cleveland Clinic Foundation, Cleveland, OH (M.M.G.); Division of 
Cardiovascular Medicine, University of Florida, Gainesville, FL (A.Y.E., A.M.); 
Division of Cardiology, University of Washington, Seattle, WA (A.N.M.); 
Cardiology Department, Hospital Universitario de La Princesa, IIS-IP, CIBER-








References 10–14, 22, 24–27, 29, and 31
REFERENCES
 1. Palmerini T, Benedetto U, Biondi-Zoccai G, Della Riva D, Bacchi-
Reggiani L, Smits PC, Vlachojannis GJ, Jensen LO, Christiansen EH, 
Berencsi K, et  al. Long- term safety of drug- eluting and bare- metal 
stents: evidence from a comprehensive network meta- analysis. J Am 
Coll Cardiol. 2015;65:2496–2507.
 2. Otsuka F, Vorpahl M, Nakano M, Foerst J, Newell JB, Sakakura K, 
Kutys R, Ladich E, Finn AV, Kolodgie FD, et al. Pathology of second- 
generation everolimus- eluting stents versus first- generation sirolimus- 
and paclitaxel- eluting stents in humans. Circulation. 2014;129: 211–223.
 3. Mahmoud AN, Barakat AF, Elgendy AY, Schneibel E, Mentias A, 
Abuzaid A, Elgendy IY. Long- term efficacy and safety of everolimus- 
eluting bioresorbable vascular scaffolds versus everolimus- eluting 
metallic stents: a meta- analysis of randomized trials. Circ Cardiovasc 
Interv. 2017;10:e005286.
 4. Kleber FX, Rittger H, Bonaventura K, Zeymer U, Wöhrle J, Jeger R, 
Levenson B, Möbius-Winkler S, Bruch L, Fischer D, et al. Drug- coated 
balloons for treatment of coronary artery disease: updated recommen-
dations from a consensus group. Clin Res Cardiol. 2013;102: 785–797.
 5. Giacoppo D, Alfonso F, Xu B, Claessen BEPM, Adriaenssens T, 
Jensen C, Pérez-Vizcayno MJ, Kang DY, Degenhardt R, Pleva L, et al. 
Paclitaxel- coated balloon angioplasty vs. drug- eluting stenting for the 
treatment of coronary in- stent restenosis: a comprehensive, collabora-
tive, individual patient data meta- analysis of 10 randomized clinical trials 
(DAEDALUS study). Eur Heart J. 2019;ehz594. DOI: 10.1093/eurheartj/
ehz594. [Epub ahead of print].
 6. Elgendy IY, Mahmoud AN, Elgendy AY, Cuesta J, Rivero F, Alfonso F. 
Meta- analysis comparing the frequency of target lesion revasculariza-
tion with drug- coated balloons or second- generation drug- eluting stents 
for coronary in- stent restenosis. Am J Cardiol. 2019;123:1186–1187.
 7. Elgendy IY, Mahmoud AN, Elgendy AY, Mojadidi MK, Elbadawi A, 
Eshtehardi P, Pérez-Vizcayno MJ, Wayangankar SA, Jneid H, David 
Anderson R, et  al. Drug- eluting balloons versus everolimus- eluting 
stents for in- stent restenosis: a meta- analysis of randomized trials. 
Cardiovasc Revasc Med. 2019;20:612–618.
 8. Siontis GC, Stefanini GG, Mavridis D, Siontis KC, Alfonso F, Pérez-
Vizcayno MJ, Byrne RA, Kastrati A, Meier B, Salanti G, et  al. 
Percutaneous coronary interventional strategies for treatment of in- 
stent restenosis: a network meta- analysis. Lancet. 2015;386:655–664.
 9. Neumann FJ, Sousa-Uva M, Ahlsson A, Alfonso F, Banning AP, 
Benedetto U, Byrne RA, Collet JP, Falk V, Head SJ, et al. 2018 ESC/
EACTS guidelines on myocardial revascularization. Eur Heart J. 
2019;40:87–165.
 10. Tang Y, Qiao S, Su X, Chen Y, Jin Z, Chen H, Xu B, Kong X, Pang W, Liu 
Y, et al. Drug- coated balloon versus drug- eluting stent for small- vessel 
disease: the RESTORE SVD China randomized trial. JACC Cardiovasc 
Interv. 2018;11:2381–2392.
 11. Jeger RV, Farah A, Ohlow MA, Mangner N, Möbius-Winkler S, 
Leibundgut G, Weilenmann D, Wöhrle J, Richter S, Schreiber M, et al. 
Drug- coated balloons for small coronary artery disease (BASKET- 
SMALL 2): an open- label randomised non- inferiority trial. Lancet. 
2018;392:849–856.
 12. Rissanen TT, Uskela S, Eränen J, Mäntylä P, Olli A, Romppanen H, 
Siljander A, Pietilä M, Minkkinen MJ, Tervo J, et al. Drug- coated balloon 
for treatment of de- novo coronary artery lesions in patients with high 
bleeding risk (DEBUT): a single- blind, randomised, non- inferiority trial. 
Lancet. 2019;394:230–239.
 13. Scheller B, Ohlow MA, Ewen S, Kische S, Rudolph TK, Clever YP, 
Wagner A, Richter S, El-Garhy M, Böhm M, et al. Randomized com-
parison of bare metal or drug- eluting stent versus drug coated bal-
loon in non- ST- elevation myocardial infarction—PEPCAD NSTEMI. 
EuroIntervention. 2020;15:1527–1533.
 14. Vos NS, Fagel ND, Amoroso G, Herrman JR, Patterson MS, Piers 
LH, van der Schaaf RJ, Slagboom T, Vink MA. Paclitaxel- coated bal-
loon angioplasty versus drug- eluting stent in acute myocardial in-
farction: the REVELATION randomized trial. JACC Cardiovasc Interv. 
2019;12:1691–1699.
 15. Hutton B, Salanti G, Caldwell DM, Chaimani A, Schmid CH, Cameron 
C, Ioannidis JP, Straus S, Thorlund K, Jansen JP, et al. The PRISMA 
extension statement for reporting of systematic reviews incorporating 
network meta- analyses of health care interventions: checklist and ex-
planations. Ann Intern Med. 2015;162:777–784.
 16. Booth A, Clarke M, Dooley G, Ghersi D, Moher D, Petticrew M, Stewart 
L. The nuts and bolts of PROSPERO: an international prospective reg-
ister of systematic reviews. Syst Rev. 2012;1:2.
 17. Higgins JP, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman 
AD, Savovic J, Schulz KF, Weeks L, Sterne JA. The Cochrane 
Collaboration’s tool for assessing risk of bias in randomised trials. BMJ. 
2011;343:d5928.
 18. DerSimonian R, Laird N. Meta- analysis in clinical trials. Control Clin 
Trials. 1986;7:177–188.
 19. Yusuf S, Peto R, Lewis J, Collins R, Sleight P. Beta blockade during and 
after myocardial infarction: an overview of the randomized trials. Prog 
Cardiovasc Dis. 1985;27:335–371.
 20. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsis-
tency in metaanalyses. BMJ. 2003;327:557–560.
 21. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta- analysis 
detected by a simple, graphical test. BMJ. 1997;315:629–634.
 22. Cortese B, Micheli A, Picchi A, Coppolaro A, Bandinelli L, Severi S, 
Limbruno U. Paclitaxel- coated balloon versus drug- eluting stent during 
PCI of small coronary vessels, a prospective randomised clinical trial. 
The PICCOLETO study. Heart. 2010;96:1291–1296.
 23. Thompson SG, Higgins JP. How should meta- regression analyses be 
undertaken and interpreted? Stat Med. 2002;21:1559–1573.
 24. Cortese B. Drug-coated balloon vs. drug-eluting stent for small coro-
nary vessel disease: 6 months primary outcome of the PICCOLETO II 
randomized clinical trial. Presented at the Transcatheter Cardiovascular 
Therapeutic meeting, San Francisco, CA, September 2019.
 25. Funatsu A, Nakamura S, Inoue N, Nanto S, Nakamura M, Iwabuchi 
M, Ando K, Asano R, Habara S, Saito S, et  al. A multicenter ran-
domized comparison of paclitaxel- coated balloon with plain balloon 
angioplasty in patients with small vessel disease. Clin Res Cardiol. 
2017;106:824–832.
 26. Latib A, Colombo A, Castriota F, Micari A, Cremonesi A, De Felice F, 
Marchese A, Tespili M, Presbitero P, Sgueglia GA, et  al. A random-
ized multicenter study comparing a paclitaxel drug- eluting balloon 
with a paclitaxel- eluting stent in small coronary vessels: the BELLO 
(Balloon Elution and Late Loss Optimization) study. J Am Coll Cardiol. 
2012;60:2473–2480.
 27. Latib A, Ruparelia N, Menozzi A, Castriota F, Micari A, Cremonesi A, De 
Felice F, Marchese A, Tespili M, Presbitero P, et al. 3- year follow- up of 
the Balloon Elution and Late Loss Optimization Study (BELLO). JACC 
Cardiovasc Interv. 2015;8:1132–1134.
 28. Gobić D, Tomulić V, Lulić D, Židan D, Brusich S, Jakljević T, Zaputović 
L. Drug- coated balloon versus drug- eluting stent in primary percutane-
ous coronary intervention: a feasibility study. Am J Med Sci. 2017;354: 
553–560.
 29. Shin ES, Lee JM, Her AY, Chung JH, Eun Lee K, Garg S, Nam CW, Doh 
JH, Koo BK. Prospective randomized trial of paclitaxel- coated balloon 
versus bare- metal stent in high bleeding risk patients with de novo cor-




 http://ahajournals.org by on M
arch 2, 2021
J Am Heart Assoc. 2020;9:e016224. DOI: 10.1161/JAHA.120.016224 11
Elgendy et al DCBs for De Novo Coronary Lesions
 30. Kleber FX, Rittger H, Ludwig J, Schulz A, Mathey DG, Boxberger M, 
Degenhardt R, Scheller B, Strasser RH. Drug eluting balloons as stand 
alone procedure for coronary bifurcational lesions: results of the random-
ized multicenter PEPCAD- BIF trial. Clin Res Cardiol. 2016;105:613–621.
 31. López Mínguez JR, Nogales Asensio JM, Doncel Vecino LJ, Sandoval J, 
Romany S, Martínez Romero P, Fernández Díaz JA, Fernández Portales 
J, González Fernández R, Martínez Cáceres G, et al. A prospective ran-
domised study of the paclitaxel- coated balloon catheter in bifurcated 
coronary lesions (BABILON trial): 24- month clinical and angiographic 
results. EuroIntervention. 2014;10:50–57.
 32. Nishiyama N, Komatsu T, Kuroyanagi T, Fujikake A, Komatsu S, 
Nakamura H, Yamada K, Nakahara S, Kobayashi S, Taguchi I. Clinical 
value of drug- coated balloon angioplasty for de novo lesions in patients 
with coronary artery disease. Int J Cardiol. 2016;222:113–118.
 33. Alfonso F, Elgendy IY, Cuesta J. Drug- coated balloons versus 
drug- eluting stents for in- stent restenosis: the saga continues. 
EuroIntervention. 2018;14:1069–1072.
 34. Katsanos K, Spiliopoulos S, Kitrou P, Krokidis M, Karnabatidis D. 
Risk of death following application of paclitaxel- coated balloons and 
stents in the femoropopliteal artery of the leg: a systematic review 
and meta- analysis of randomized controlled trials. J Am Heart Assoc. 
2018;7:e011245. DOI: 10.1161/JAHA.118.011245.
 35. Beckman JA, White CJ. Paclitaxel- coated balloons and eluting stents: 
is there a mortality risk in patients with peripheral artery disease? 
Circulation. 2019;140:1342–1351.
 36. Freisinger E, Koeppe J, Gerss J, Goerlich D, Malyar NM, Marschall 
U, Faldum A, Reinecke H. Mortality after use of paclitaxel- based de-
vices in peripheral arteries: a real- world safety analysis. Eur Heart J. 
2019;ehz698. DOI: 10.1093/eurheartj/ehz698. [Epub ahead of print].
 37. Schneider PA, Laird JR, Doros G, Gao Q, Ansel G, Brodmann M, Micari 
A, Shishehbor MH, Tepe G, Zeller T. Mortality not correlated with pacl-
itaxel exposure: an independent patient- level meta- analysis of a drug- 
coated balloon. J Am Coll Cardiol. 2019;73:2550–2563.
 38. Megaly M, Rofael M, Saad M, Rezq A, Kohl LP, Kalra A, Shishehbor M, 
Soukas P, Abbott JD, Brilakis ES. Outcomes with drug- coated balloons 
in small- vessel coronary artery disease. Catheter Cardiovasc Interv. 
2019;93:E277–E286.
 39. Li M, Guo C, Lv YH, Zhang MB, Wang ZL. Drug- coated balloon ver-
sus drug- eluting stent in de novo small coronary vessel disease: a 
systematic review and meta- analysis. Medicine (Baltimore). 2019;98: 
e15622.
 40. Megaly M, Rofael M, Saad M, Shishehbor M, Brilakis ES. Outcomes 
with drug- coated balloons for treating the side branch of coronary bi-










 http://ahajournals.org by on M
arch 2, 2021
Table S1. Search strategy.
Database Search Strategy Filters Number  
Pubmed ((Eluting balloon AND coronary) OR (coated balloon AND coronary) Human Species 326 
CENTRAL ((Eluting balloon) OR (coated balloon) AND (coronary)) Clinical trials 131 
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Table S2.  Definition of major adverse cardiac events per the individual trials.
Trial (ref#) Definition of major adverse cardiac events 
PICCOLETO II24  Cardiac death, non-fatal myocardial infarction, target lesion revascularization 
RESTORE SVD10  Cardiac death, target vessel myocardial infarction, target lesion revascularization 
BASKET-SMALL 211  Cardiac death, non-fatal myocardial infarction, target vessel revascularization 
Funatsu et al25  Cardiac death, non-fatal myocardial infarction, target vessel revascularization 
BELLO26,27  All-cause death, non-fatal myocardial infarction, target vessel revascularization 
PICCOLETO22  Death, ST elevation myocardial infarction, target lesion revascularization 
PEPCAD NSTEMI13  Cardiac death, non-fatal myocardial infarction, target lesion revascularization 
REVELATION14  Cardiac death, non-fatal myocardial infarction, target lesion revascularization 
Gobic et al28  Cardiac death, non-fatal myocardial infarction, target lesion revascularization, stent thrombosis 
Shin et al29  Cardiac death, non-fatal myocardial infarction, target lesion revascularization, stent thrombosis 
DEBUT12  Cardiac death, non-fatal myocardial infarction, target lesion revascularization 
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Table S3. Baseline patient and trial characteristics. 






PICCOLETO II24  Multicenter Italy NCT03899818 64/66 70/77 38/35 65/67 45/44 
RESTORE SVD10  Multicenter China NCT02946307 60/61 66/77 40/42 67/75 69/71 
BASKET-SMALL 211  Multicenter Switzerland, Germany, Austria NCT01574534 67/68 77/70 32/35 85/89 30/27 
Funatsu et al25  Multicenter Japan UMIN000026760 68/69 78/68 48/32 84/73 NR 
BELLO26,27  Multicenter Italy NCT01086579 65/66 80/77 43/38 80/82 24/22 
PICCOLETO22  Single center Italy EudraCT: 2009-012268-15 68/67 79/76 38/46 75/71 54/55 
PEPCAD NSTEMI13  Multicenter Germany NCT01489449 66/67 66/68 27/36 79/88 100/100 
REVELATION14  Single center Netherlands NCT02219802 57/57 87/87 13/7 30/32 100/100 
Gobic et al28  Single center Croatia NR 57/54 71/73 5/11 32/35 100/100 
Shin et al29  Single center Korea NCT02456402 58/62 70/75 35/25 40/45 30/40 
DEBUT12  Multicenter Finland NCT01781546 78/76 62/64 26/49 MACE 46/46 
PEPCAD-BIF30  Multicenter Germany NR 66/69 75/72 34/38 87/91 28/19 
BABILON31  Multicenter Spain NCT01278186 64/66 64/66 27/38 NR 68 
Nishiyama et al32  Single center Japan NR 67/70 67/80 40/43 77/90 100/100 
Data are reported as drug-coated balloon/control 
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Table S4.  Risk of bias of the individual studies by Cochrane risk assessment tool.  






BELLO26,27 PICCOLETO22  PEPCAD 
NSTEMI13  
REVELATION14  Gobic  
et al28 
Shin  
et al29  
DEBUT12  PEPCAD-
BIF30
BABILON31  Nishiyama 
et al32
Random sequence 
generation (Selection bias) 
Allocation concealment 
(Selection bias) 
Blinding of participants 
and personnel 
(Performance bias)
Blinding of outcome 
assessment (Detection 
bias) 




Other sources of bias 
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